



Cancer Heterogeneity: Biomarkers and Targeted Therapies

Guest Editors:

Dr. Verónica Rodilla

Josep Carreras Leukaemia
Research Institute, 08916
Badalona, Spain

Dr. Cristina Guardia

Josep Carreras Leukaemia
Research Institute, 08916
Badalona, Spain

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

Cancer cannot be understood as a single disease but rather a collection of distinct tumor subtypes. Tumor cells are extremely plastic and dynamic, and the diversity of phenotypes observed in tumors reflects the array of cell types present in the tumor. The extended use of cutting-edge technologies such as single-cell and spatially resolved transcriptomics provides powerful tools to unravel molecular and cellular features of tumor heterogeneity, with the great potential of being translated into new and reliable biomarkers, and novel targeted therapies. In this Special Issue, we invite reviews and original research manuscripts that examine how cancer heterogeneity can be exploited to identify new biomarkers and molecular drivers responsible for tumor maintenance, circumvent drug resistance, and/or develop effective targeted therapies in the path of getting closer the personalized medicine to cancer patients.

- tumor heterogeneity
- biomarkers
- targeted therapies
- personalized medicine





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI